AR102096A1 - Proceso para elaborar acetato de glatiramer - Google Patents
Proceso para elaborar acetato de glatiramerInfo
- Publication number
- AR102096A1 AR102096A1 ARP150103103A ARP150103103A AR102096A1 AR 102096 A1 AR102096 A1 AR 102096A1 AR P150103103 A ARP150103103 A AR P150103103A AR P150103103 A ARP150103103 A AR P150103103A AR 102096 A1 AR102096 A1 AR 102096A1
- Authority
- AR
- Argentina
- Prior art keywords
- glatiramer acetate
- mannitol
- aqueous pharmaceutical
- pharmaceutical solution
- appropriate container
- Prior art date
Links
- 108010072051 Glatiramer Acetate Proteins 0.000 title abstract 5
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 title abstract 5
- 229960003776 glatiramer acetate Drugs 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 4
- 229930195725 Mannitol Natural products 0.000 abstract 4
- 235000010355 mannitol Nutrition 0.000 abstract 4
- 239000000594 mannitol Substances 0.000 abstract 4
- 239000003186 pharmaceutical solution Substances 0.000 abstract 4
- 239000000706 filtrate Substances 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 229940071643 prefilled syringe Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un proceso para elaborar un preparado farmacéutico de acetato de glatiramer y manitol en un recipiente apropiado que comprende los siguientes pasos: (i) obtener una solución farmacéutica acuosa de acetato de glatiramer y manitol; (ii) filtrar la solución farmacéutica acuosa a una temperatura entre más de 0ºC y 17,5ºC para obtener un filtrado; y (iii) llenar el recipiente apropiado con el filtrado que se obtiene luego de llevar a cabo el paso (ii), de manera tal de obtener así el preparado farmacéutico de acetato de glatiramer y manitol en el recipiente apropiado. Esta provee además una solución farmacéutica acuosa que comprende 40 mg/ml de acetato de glatiramer y 40 mg/ml de manitol, donde la solución farmacéutica acuosa a) tiene una viscosidad dentro del rango entre 2,0 - 3,5 cPa; o b) tiene una osmolalidad dentro del rango entre 275 - 325 mosmol/Kg. Esta también provee una jeringa precargada, un inyector automatizado y un método para tratar un paciente humano.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/608,126 US9155775B1 (en) | 2015-01-28 | 2015-01-28 | Process for manufacturing glatiramer acetate product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR102096A1 true AR102096A1 (es) | 2017-02-01 |
Family
ID=54199060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150103103A AR102096A1 (es) | 2015-01-28 | 2015-09-25 | Proceso para elaborar acetato de glatiramer |
Country Status (30)
| Country | Link |
|---|---|
| US (6) | US9155775B1 (es) |
| EP (3) | EP3113785A4 (es) |
| JP (2) | JP2018503627A (es) |
| KR (2) | KR102268210B1 (es) |
| CN (1) | CN107530394B (es) |
| AR (1) | AR102096A1 (es) |
| AU (4) | AU2015380381B2 (es) |
| BR (1) | BR112016023736A2 (es) |
| CA (2) | CA2965890A1 (es) |
| CL (1) | CL2016002607A1 (es) |
| CY (1) | CY1118826T1 (es) |
| DK (1) | DK3050556T3 (es) |
| EA (3) | EA028484B1 (es) |
| ES (1) | ES2584190T3 (es) |
| HK (1) | HK1225309B (es) |
| HR (1) | HRP20170625T1 (es) |
| HU (1) | HUE034059T2 (es) |
| IL (3) | IL247851A0 (es) |
| LT (1) | LT3050556T (es) |
| ME (1) | ME02721B (es) |
| MX (1) | MX352734B (es) |
| PE (1) | PE20170296A1 (es) |
| PL (1) | PL3050556T3 (es) |
| PT (1) | PT3050556T (es) |
| RS (1) | RS55959B1 (es) |
| RU (1) | RU2669769C2 (es) |
| SI (1) | SI3050556T1 (es) |
| UA (1) | UA116060C2 (es) |
| WO (1) | WO2016122722A1 (es) |
| ZA (1) | ZA201606903B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| BR112013008573A2 (pt) | 2010-10-11 | 2016-07-12 | Teva Pharma | citocinas biomarcadoras como indicadores de resposta clínica a acetato de glatirâmer. |
| EA201490749A1 (ru) | 2011-10-10 | 2014-09-30 | Тева Фармасьютикал Индастриз Лтд. | Однонуклеотидные полиморфизмы, полезные для прогнозирования клинической реакции на глатирамера ацетат |
| EP2906719A4 (en) | 2012-10-10 | 2016-11-09 | Teva Pharma | PREDICTIVE BIOMARKER FOR CLINICAL REACTION FOR GLATIRAMERACETATE |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
| CN107550853B (zh) * | 2016-06-30 | 2020-06-12 | 深圳翰宇药业股份有限公司 | 一种醋酸格拉替雷注射液的制备方法 |
| EP3551046B1 (en) | 2016-12-07 | 2023-07-19 | Biora Therapeutics, Inc. | Gastrointestinal tract detection methods, devices and systems |
| CA3050086A1 (en) | 2017-03-26 | 2018-10-04 | Mapi Pharma Ltd. | Glatiramer depot systems for treating progressive forms of multiple sclerosis |
| US20200306516A1 (en) | 2017-08-14 | 2020-10-01 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with glatiramer or a pharmaceutically acceptable salt thereof |
| CN112933210A (zh) * | 2019-12-11 | 2021-06-11 | 深圳翰宇药业股份有限公司 | 一种西曲瑞克冻干药物组合物的制备方法 |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL36670A (en) | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| FR2459619B1 (fr) | 1979-06-26 | 1983-07-29 | Agronomique Inst Nat Rech | Procede pour l'obtention a partir de lactoserum, d'un produit enrichi en alpha-lactalbumine et applications dudit procede |
| US4350156A (en) | 1980-05-29 | 1982-09-21 | Japan Foundation For Artificial Organs | Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid |
| US4455256A (en) | 1981-05-05 | 1984-06-19 | The Regents Of The University Of California | Bone morphogenetic protein |
| DE69427226T2 (de) | 1993-03-24 | 2001-08-30 | Owen Mumford Ltd., Woodstock | Vorrichtung zur injektion |
| IL113812A (en) | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
| US5631347A (en) | 1995-06-07 | 1997-05-20 | Eli Lilly And Company | Reducing gelation of a fatty acid-acylated protein |
| DE19543737A1 (de) | 1995-11-24 | 1997-05-28 | Hoechst Ag | Verfahren zur Ultrafiltration von Peptide oder Proteine enthaltender biologischer Matrices |
| IL119989A0 (en) | 1997-01-10 | 1997-04-15 | Yeda Res & Dev | Pharmaceutical compositions for oral treatment of multiple sclerosis |
| US6214791B1 (en) | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
| IL140592A0 (en) | 1998-07-23 | 2002-02-10 | Harvard College | Synthetic peptides and methods of use for autoimmune disease therapies |
| ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| EP1098902A4 (en) | 1998-07-23 | 2002-07-24 | Yeda Res & Dev | TREATMENT OF AUTOIMMUNE DISEASES BY COPOLYMER 1 AND SIMILAR COPOLYMERS AND PEPTIDES |
| US6514938B1 (en) | 1998-09-25 | 2003-02-04 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| PT2239269E (pt) | 1998-09-25 | 2013-04-09 | Yeda Res & Dev | Uso de péptidos derivados de copolímero 1 como marcadores de peso molecular |
| AU6281599A (en) | 1998-10-02 | 2000-04-26 | Yeda Research And Development Co. Ltd. | Alternate day administration of copolymer 1 for treating autoimmune diseases |
| AU775073C (en) | 1998-11-12 | 2007-05-03 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD |
| ATE329608T1 (de) | 2000-02-18 | 2006-07-15 | Yeda Res & Dev | Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung |
| US7022663B2 (en) | 2000-02-18 | 2006-04-04 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
| US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| HUP0302333A3 (en) | 2000-06-05 | 2005-07-28 | Teva Pharma | The use of glatiramer acetate (copolymer 1) for the preparation of pharmaceutical compositions available in the treatment of central nervous system disorders |
| WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| DE10158009A1 (de) * | 2001-11-21 | 2003-05-28 | Begerow E Gmbh & Co | Verfahren zur Reduzierung der Gesamtkeimzahl in wäßrigen Dispersionen |
| CN1308683C (zh) | 2001-12-04 | 2007-04-04 | 特瓦制药工业有限公司 | 测量醋酸格拉默功效的方法 |
| CA2411786C (en) | 2002-11-13 | 2009-01-27 | Brantford Chemicals Inc. | A process for the preparation of polypeptides from n-carboxyanhydrides of amino acids |
| US7777006B2 (en) | 2002-12-31 | 2010-08-17 | Csl Behring L.L.C. | Method for purification of alpha-1-antitrypsin |
| MXPA05007711A (es) | 2003-01-21 | 2005-09-30 | Yeda Res & Dev | Copolimero 1 para el tratamiento de enfermedades inflamatorias del intestino. |
| CA2518079A1 (en) | 2003-03-04 | 2004-10-28 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis |
| US7968511B2 (en) | 2003-05-14 | 2011-06-28 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis |
| WO2005035088A2 (en) | 2003-07-18 | 2005-04-21 | Baxter International, Inc. | Method for preparing small spherical by controlled phase separation |
| US20050170004A1 (en) | 2003-10-31 | 2005-08-04 | Vered Rosenberger | Nanoparticles for drug delivery |
| EP1701971A2 (en) | 2003-12-31 | 2006-09-20 | F.Hoffmann-La Roche Ag | Peptide synthesis using decanting filter |
| CA2558380A1 (en) | 2004-03-03 | 2005-09-15 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and riluzole |
| US7655221B2 (en) | 2004-05-07 | 2010-02-02 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
| US20060194725A1 (en) | 2004-05-07 | 2006-08-31 | James Rasmussen | Methods of treating disease with random copolymers |
| US20090048181A1 (en) | 2004-09-02 | 2009-02-19 | Schipper Hyman M | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis |
| US7560100B2 (en) | 2004-09-09 | 2009-07-14 | Yeda Research And Development Co., Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases |
| PL2361924T3 (pl) | 2004-09-09 | 2014-08-29 | Teva Pharma | Proces przygotowania mieszanin octanu trifluoroacetyloglatirameru z zastosowaniem oczyszczonego kwasu bromowodorowego |
| AR052321A1 (es) | 2004-10-29 | 2007-03-14 | Sandoz Ag | Procesos para la preparacion de un polipeptido |
| CA2594022A1 (en) | 2005-02-02 | 2006-08-10 | Teva Pharmaceutical Industries Ltd. | Process for producing polypeptide mixtures using hydrogenolysis |
| US20100167983A1 (en) | 2007-10-22 | 2010-07-01 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| US20080261894A1 (en) | 2005-02-17 | 2008-10-23 | Rivka Kreitman | Combination Therapy with Glatiramer Acetate and Rasagiline for the Treatment of Multiple Sclerosis |
| EP1891233A4 (en) | 2005-04-25 | 2010-03-24 | Yeda Res & Dev | MARKERS ASSOCIATED WITH THERAPY EFFECTIVENESS OF GLATIRAMERATE ACETATE |
| WO2007030573A2 (en) | 2005-09-09 | 2007-03-15 | Yeda Research And Development Co. Ltd. | Polypeptides useful for molecular weight determinations |
| WO2007081975A2 (en) | 2006-01-11 | 2007-07-19 | Teva Pharmaceutical Industries, Ltd. | Method of treating multiple sclerosis |
| US20080118553A1 (en) | 2006-06-12 | 2008-05-22 | Anton Frenkel | Tannate salt form of polypeptide mixtures, their preparation and use |
| EP2143728A1 (en) | 2006-07-05 | 2010-01-13 | Momenta Pharmaceuticals, Inc. | Improved process for the preparation of copolymer-1 |
| CN100569282C (zh) | 2006-10-13 | 2009-12-16 | 俞嘉林 | 注射用骨肽冻干剂及其制备方法 |
| CN101743470A (zh) | 2007-06-21 | 2010-06-16 | 动量制药公司 | 共聚物测定 |
| US8993722B2 (en) | 2007-07-31 | 2015-03-31 | Natco Pharma Limited | Process for the preparation glatiramer acetate (copolymer-1) |
| MX2010005676A (es) | 2007-11-28 | 2010-08-06 | Teva Pharma | Metodo para retrasar el comienzo de esclerosis multiple clinicamente definida. |
| CN103417472B (zh) | 2008-05-14 | 2018-01-02 | 奥德纳米有限公司 | 用于治疗耳部病症的控制释放皮质类固醇组合物和方法 |
| US8323685B2 (en) | 2008-08-20 | 2012-12-04 | Baxter International Inc. | Methods of processing compositions containing microparticles |
| US8920373B2 (en) | 2009-07-15 | 2014-12-30 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
| CA2697570C (en) | 2009-07-15 | 2011-11-01 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
| LT2949335T (lt) * | 2009-08-20 | 2017-03-27 | Yeda Research & Development Company, Ltd. | Žemo dažnio glatiramero acetato terapija |
| ITMI20092069A1 (it) | 2009-11-25 | 2011-05-26 | Biofer Spa | Metodo per ottenere una miscela di fattori biologici isolati da colostro e miscela di fattori biologici attivi derivata da colostro. |
| US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| BR112013008573A2 (pt) | 2010-10-11 | 2016-07-12 | Teva Pharma | citocinas biomarcadoras como indicadores de resposta clínica a acetato de glatirâmer. |
| EP2675824B1 (en) | 2011-02-14 | 2017-09-27 | USV Private Limited | Copolymer-1, process for preparation and analytical methods thereof |
| US8575198B1 (en) * | 2011-09-07 | 2013-11-05 | Momenta Pharmaceuticals, Inc. | In-process control for the manufacture of glatiramer acetate |
| EA201490749A1 (ru) | 2011-10-10 | 2014-09-30 | Тева Фармасьютикал Индастриз Лтд. | Однонуклеотидные полиморфизмы, полезные для прогнозирования клинической реакции на глатирамера ацетат |
| JP6389170B2 (ja) * | 2012-07-06 | 2018-09-12 | スリーディー マトリックス， エルティーディー３−Ｄ Ｍａｔｒｉｘ， Ｌｔｄ． | ペプチド溶液のためのフィル−フィニッシュ過程 |
| EP2906719A4 (en) | 2012-10-10 | 2016-11-09 | Teva Pharma | PREDICTIVE BIOMARKER FOR CLINICAL REACTION FOR GLATIRAMERACETATE |
| JP2016504039A (ja) | 2013-01-04 | 2016-02-12 | テバ ファーマシューティカル インダストリーズ リミティド | グラチラマーアセテート関連医薬品の特性決定 |
| WO2014128079A1 (en) | 2013-02-19 | 2014-08-28 | Synthon B.V. | Glatiramer acetate multidose formulation |
| CA2903127A1 (en) | 2013-03-12 | 2014-10-09 | Teva Pharmaceutical Industries Ltd. | Rituximab induction therapy followed by glatiramer acetate therapy |
| CN103169670B (zh) * | 2013-03-22 | 2016-07-06 | 深圳翰宇药业股份有限公司 | 一种醋酸格拉替雷微球及其制备方法 |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
-
2015
- 2015-01-28 US US14/608,126 patent/US9155775B1/en active Active
- 2015-09-21 CA CA2965890A patent/CA2965890A1/en not_active Abandoned
- 2015-09-21 WO PCT/US2015/051203 patent/WO2016122722A1/en active Application Filing
- 2015-09-21 RU RU2017104222A patent/RU2669769C2/ru active
- 2015-09-21 JP JP2017534813A patent/JP2018503627A/ja not_active Withdrawn
- 2015-09-21 CA CA2945537A patent/CA2945537C/en active Active
- 2015-09-21 PE PE2016001955A patent/PE20170296A1/es unknown
- 2015-09-21 KR KR1020177012458A patent/KR102268210B1/ko active IP Right Grant
- 2015-09-21 EP EP15880609.1A patent/EP3113785A4/en not_active Withdrawn
- 2015-09-21 CN CN201580071551.XA patent/CN107530394B/zh active Active
- 2015-09-21 MX MX2016011219A patent/MX352734B/es active IP Right Grant
- 2015-09-21 UA UAA201610444A patent/UA116060C2/uk unknown
- 2015-09-21 AU AU2015380381A patent/AU2015380381B2/en active Active
- 2015-09-21 US US14/860,053 patent/US9763993B2/en active Active
- 2015-09-21 EA EA201691790A patent/EA028484B1/ru unknown
- 2015-09-21 US US15/510,156 patent/US20170312331A1/en not_active Abandoned
- 2015-09-21 KR KR1020167028604A patent/KR101737295B1/ko active IP Right Grant
- 2015-09-21 BR BR112016023736A patent/BR112016023736A2/pt not_active Application Discontinuation
- 2015-09-24 LT LTEP15186721.5T patent/LT3050556T/lt unknown
- 2015-09-24 HU HUE15186721A patent/HUE034059T2/en unknown
- 2015-09-24 EP EP15186721.5A patent/EP3050556B1/en not_active Revoked
- 2015-09-24 ES ES15186721.5T patent/ES2584190T3/es active Active
- 2015-09-24 EP EP17162112.1A patent/EP3238706A1/en not_active Withdrawn
- 2015-09-24 DK DK15186721.5T patent/DK3050556T3/en active
- 2015-09-24 RS RS20170439A patent/RS55959B1/sr unknown
- 2015-09-24 ME MEP-2017-103A patent/ME02721B/me unknown
- 2015-09-24 SI SI201530058A patent/SI3050556T1/sl unknown
- 2015-09-24 PL PL15186721T patent/PL3050556T3/pl unknown
- 2015-09-24 PT PT151867215T patent/PT3050556T/pt unknown
- 2015-09-25 AR ARP150103103A patent/AR102096A1/es unknown
- 2015-09-25 EA EA201791555A patent/EA201791555A3/ru unknown
- 2015-09-25 EA EA201500881A patent/EA028811B1/ru unknown
-
2016
- 2016-08-16 AU AU2016101453A patent/AU2016101453B4/en not_active Expired
- 2016-09-15 IL IL247851A patent/IL247851A0/en unknown
- 2016-10-07 ZA ZA2016/06903A patent/ZA201606903B/en unknown
- 2016-10-13 CL CL2016002607A patent/CL2016002607A1/es unknown
- 2016-12-01 HK HK16113726A patent/HK1225309B/zh unknown
- 2016-12-14 AU AU2016273881A patent/AU2016273881A1/en not_active Abandoned
-
2017
- 2017-03-28 US US15/471,765 patent/US20170196930A1/en not_active Abandoned
- 2017-04-13 CY CY20171100442T patent/CY1118826T1/el unknown
- 2017-04-21 HR HRP20170625TT patent/HRP20170625T1/hr unknown
- 2017-09-18 US US15/707,378 patent/US20180000884A1/en not_active Abandoned
- 2017-10-19 US US15/788,698 patent/US20180036363A1/en not_active Abandoned
-
2018
- 2018-01-23 AU AU2018200518A patent/AU2018200518A1/en not_active Abandoned
- 2018-07-17 JP JP2018134124A patent/JP6592150B2/ja active Active
-
2019
- 2019-06-06 IL IL267152A patent/IL267152A/en unknown
-
2020
- 2020-09-24 IL IL277601A patent/IL277601B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR102096A1 (es) | Proceso para elaborar acetato de glatiramer | |
| ZA202102906B (en) | Liquid protein formulations containing viscosity-lowering agents | |
| BR112018008880A8 (pt) | composto 7-(tiazol-5-il) pirrolopirimidina como agonista de tlr7 | |
| EA201690207A1 (ru) | Композиция традиционной китайской медицины и препарат из нее и их применение | |
| EA201691918A1 (ru) | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения | |
| MX356639B (es) | Anticongelante de yema de huevo de pato para la crioconservacion de semen de burro y el metodo de preparacion del mismo. | |
| TN2017000011A1 (en) | Aqueous formulation comprising paracetamol and ibuprofen. | |
| AR100618A1 (es) | Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido | |
| BR112016015190A2 (pt) | Composição farmacêutica não contendo antioxidante e método de preparação da mesma | |
| DOP2016000251A (es) | Inhibidores de las vías de señalización de wnt | |
| CO2018002428A2 (es) | Amida seleccionada de ácido gamma-hidroxiburico y usos de la misma en el tratamiento de abuso de alcohol | |
| AR099558A1 (es) | Régimen de dosaje del compuesto fgf-18 | |
| MX362905B (es) | Tratamiento de combinacion. | |
| MX359887B (es) | Composicion masticable para administracion oral y proceso para preparar la misma. | |
| PH12017501005A1 (en) | Injectable formulations of paracetamol | |
| MX2018001041A (es) | Concentrado que contiene alprostadil. | |
| EA201600331A1 (ru) | Фармацевтическая композиция в форме раствора для внутривенного и внутримышечного введения и способ ее получения | |
| EA027609B8 (ru) | Способ получения интерферона бета-1альфа и фармацевтическая композиция, содержащая интерферон бета-1альфа | |
| MX2015010517A (es) | Composicion de estabilidad mejorada de etanercept. | |
| RU2013100450A (ru) | Способ лечения желчнокаменной болезни в эксперименте | |
| CU20140150A7 (es) | Proceso para producir solución de acetaminofén supersaturada inyectable de administración por la espina dorsal | |
| AR096092A1 (es) | ANTICUERPOS ANTI-IGF-1R CON ABOLICIÓN DE LA UNIÓN AL FcRn Y SU UTILIZACIÓN EN EL TRATAMIENTO DE ENFERMEDADES OCULARES VASCULARES | |
| TH162713A (th) | ยาชนิดรวมที่ประกอบรวมด้วยเจมิกลิปทินและเมตฟอร์มินและวิธีการสำหรับ การเตรียมยาชนิดรวมดังกล่าว | |
| TH162713B (th) | ยาชนิดรวมที่ประกอบรวมด้วยเจมิกลิปทินและเมตฟอร์มินและวิธีการสำหรับ การเตรียมยาชนิดรวมดังกล่าว | |
| IN2013MU03613A (es) |